bioRxivBiophysicsPreprint
Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease
S. Günther, P. Y. A. Reinke, D. Oberthuer, O. Yefanov, H. Ginn, S. Meier, T. J. Lane, K. Lorenzen, L. Gelisio, W. BrehmiD, I. Dunkel, M. Domaracky, S. Saouane, J. Lieske, C. Ehrt, F. KouaiD, A. Tolstikova, T. A. White, M. Groessler, H. Fleckenstein, F. TrostiD, M. Galchenkova, Y. GevorkoviD, C. Li, S. Awel, , G
Abstract
Here we present the crystal structure of SARS-CoV-2 main protease (Mpro) covalently bound to 2-methyl-1-tetralone. This complex was obtained by co-crystallization of Mpro with HEAT (2-(((4-hydroxyphenethyl)amino)methyl)-3,4-dihydronaphthalen-1(2H)-one) in the framework of a large X-ray crystallographic screening project of Mpro against a drug repurposing library, consisting of 5632 approved drugs or compounds in clinical phase trials. Further investigations showed that HEAT is cleaved by Mpro in an E1cB-like reaction mechanism into 2-methylene-1-tetralone and tyramine. The catalytic Cys145 subsequently binds covalently in a Michael addition to the methylene carbon atom of 2-methylene-1-tetralone. According to this postulated model HEAT is acting in a pro-drug-like fashion. It is metabolized by Mpro, followed by covalent binding of one metabolite to the active site. The structure of the covalent adduct elucidated in this study opens up a new path for developing non-peptidic inhibitors.
- assay: structural biology
- research focus: protein structure prediction
- research focus: drug response / drug discovery
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity
N. Kitamura, M. D. Sacco, … J. Wang·bioRxiv·Dec 19, 2020
- Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L
M. D. Sacco, C. Ma, … J. Wang·Science AdvancesPeer-reviewed·Dec 11, 2020
- Conserved interactions required for in vitro inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
A. Shitrit, D. Zaidman, … O. Kobiler·bioRxiv·Sep 10, 2020
- Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease
D. W. Kneller, G. Phillips, … A. Kovalevsky·bioRxiv·Jan 12, 2021
- Acrylamide Fragment Inhibitors that Induce Unprecedented Conformational Distortions in Enterovirus 71 3C and SARS-CoV-2 Main Protease
B. Qin, G. B. Craven, … S. Cui·bioRxiv·Nov 6, 2020
- Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin